Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

IMPORTANCE: Numerous cancer drugs have received accelerated approval from the US Food and Drug Administration (FDA) based on clinical trial outcomes that are otherwise not acceptable for traditional FDA approval; the accelerated approval process allows outcomes based on surrogate measures that are o...

Descripción completa

Detalles Bibliográficos
Autores principales: Cherla, Avi, Naci, Huseyin, Kesselheim, Aaron S., Gyawali, Bishal, Mossialos, Elias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900925/
https://www.ncbi.nlm.nih.gov/pubmed/33616607
http://dx.doi.org/10.1001/jamainternmed.2020.8441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900925/
https://www.ncbi.nlm.nih.gov/pubmed/33616607
http://dx.doi.org/10.1001/jamainternmed.2020.8441

Ejemplares similares